CD274 and non-small cell lung carcinoma: Similarly, Nicolazzo et al. demonstrated that the presence of PD-L1+ CTCs at baseline and after 3 and 6 months of treatment with nivolumab correlated with progression and a worsened clinical outcome of NSCLC, suggesting that the persistence of this population might be a mechanism of resistance [33].